Literature DB >> 8820968

FOS expression in the brainstem and cerebellum following phencyclidine and MK801.

R Näkki1, F R Sharp, S M Sagar.   

Abstract

The non-competitive N-methyl-D-aspartate (NMDA) receptor antagonists phencyclidine (PCP) and dizocilpine maleate (MK801) cause nystagmus, tremor, and cerebellar ataxia at toxic doses. We have shown that PCP but not MK801 is toxic to rat cerebellar Purkinje cells. To study the mechanism and pathways of PCP and MK801 action, Fos protein expression was examined in the cerebellum and functionally related nuclei of the brainstem. PCP, 1-50 mg/kg i.p., induced Fos immunostaining in neurons of the inferior olive, cerebellar granule cell layer, and deep cerebellar and vestibular nuclei. At higher doses, PCP, 25-50 mg/kg, induced dense Fos immunoreactivity throughout the inferior olive except for rostral parts of medial accessory olive and caudal parts of principal olive. At lower doses of PCP, 1-10 mg/kg, Fos positive cells in inferior olive were concentrated in the subnucleus beta. In the cerebellum Fos positive granule cells were arranged in patches distributed throughout the cerebellar cortex following PCP, 1-50 mg/kg. Rare Fos positive Purkinje cells were observed adjacent to these patches. At the highest dose of PCP tested (50 mg/kg), Fos was expressed in the fastigial, interpositus, and dentate nuclei, and in vestibular nuclei, most prominently in the medial vestibular nucleus. At lower doses, Fos was expressed mainly in medial cerebellar output nuclei and in vestibular nuclei. MK801, 0.2-10 mg/kg i.p., induced Fos expression in the same regions as PCP. However, MK801-induced Fos expression in inferior olive was localized primarily to subnucleus beta. No apparent differences in the number or distribution of Fos positive neurons were observed at MK801 doses of 0.2-10 mg/kg. MK801 also induced Fos expression in fastigial and vestibular nuclei, but not in lateral (interpositus and dentate) cerebellar nuclei. MK801, 0.2-10 mg/kg, induced patchy Fos expression in cerebellar granule cells that was similar to PCP. These results support our earlier observations that PCP and MK801 have different actions in the cerebellum, although they both cause ataxia and indistinguishable behavioral symptoms. That high doses of PCP induce substantially more Fos expression in inferior olive than MK801 suggests that its toxicity to Purkinje cells is at least partially the result of excessive activity of climbing fibers, the excitatory neural input that arises from the inferior olive and synapses on Purkinje cell dentrities.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8820968     DOI: 10.1002/(SICI)1097-4547(19960115)43:2<203::AID-JNR8>3.0.CO;2-K

Source DB:  PubMed          Journal:  J Neurosci Res        ISSN: 0360-4012            Impact factor:   4.164


  5 in total

1.  Expression profiling to understand actions of NMDA/glutamate receptor antagonists in rat brain.

Authors:  Petri Törönen; Marcus Storvik; Anni-Maija Lindén; Outi Kontkane; Markéta Marvanová; Merja Lakso; Eero Castrén; Garry Wong
Journal:  Neurochem Res       Date:  2002-10       Impact factor: 3.996

Review 2.  Modulation of NMDA receptors in the cerebellum. II. Signaling pathways and physiological modulators regulating NMDA receptor function.

Authors:  Ana Sanchez-Perez; Marta Llansola; Omar Cauli; Vicente Felipo
Journal:  Cerebellum       Date:  2005       Impact factor: 3.847

Review 3.  Drugs of abuse and immediate-early genes in the forebrain.

Authors:  R E Harlan; M M Garcia
Journal:  Mol Neurobiol       Date:  1998-06       Impact factor: 5.590

4.  Modular output circuits of the fastigial nucleus for diverse motor and nonmotor functions of the cerebellar vermis.

Authors:  Hirofumi Fujita; Takashi Kodama; Sascha du Lac
Journal:  Elife       Date:  2020-07-08       Impact factor: 8.140

5.  Effects of NMDA-receptor antagonist treatment on c-fos expression in rat brain areas implicated in schizophrenia.

Authors:  Jussi Väisänen; Jouni Ihalainen; Heikki Tanila; Eero Castrén
Journal:  Cell Mol Neurobiol       Date:  2004-12       Impact factor: 5.046

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.